scholarly journals A retrospective analysis of the correlation between AXL expression and clinical outcomes of patients with urothelial bladder carcinoma

2019 ◽  
Vol 8 (3) ◽  
pp. 976-984
Author(s):  
Lining Wang ◽  
Kangkang Liu ◽  
Jianpeng Yu ◽  
Erlin Sun
Keyword(s):  
Retrospective Analysis ◽  
Clinical Outcomes ◽  
Bladder Carcinoma ◽  
Urothelial Bladder Carcinoma ◽  
Urothelial Bladder

scholarly journals PD-1/PD-L1 Immune Checkpoint Inhibitors after Platinum-based Chemotherapy in Metastatic or Locally Advanced Urothelial Bladder Carcinoma: A Systematic Review and Meta-analysis

2021 ◽  
Author(s):  
Thara Tunthanathip ◽  
Tanan Bejrananda
Keyword(s):  
Systematic Review ◽  
Overall Survival ◽  
Cell Death ◽  
Bladder Carcinoma ◽  
Meta Analysis ◽  
Locally Advanced ◽  
Second Line ◽  
Urothelial Bladder Carcinoma ◽  
Urothelial Bladder ◽  
Line Chemotherapy

Objective: This study aimed to assess the effect of anti-programmed cell death-1/programmed cell death-ligand-1 (PD-1/PD-L1) agents compared with second-line therapy in patients with metastatic or locally advanced urothelial bladder carcinoma following previous platinum-containing chemotherapy.Material and Methods: We systematically searched three electronic databases. The protocol of the study was registered in Prospero (CRD42019142494). Using the Grading of Recommendations Assessment, Development, and Evaluation approach, the certainty of evidence (CoE) was estimated.Results: The search results initially found 8168 publications. For qualitative synthesis, two publications were included. Pooled results indicated that patients treated with anti-PD-1/PD-L1 agents had significantly prolonged overall survival (hazard ratio (HR) 0.80; 95% confidence interval (CI) 0.7-0.9; I2 21.0%; moderate CoE). According to positive PD-L1 expression, PD-1/PD-L1 inhibitors had significantly more survival than chemotherapy (HR 0.75; 95% CI 0.5-0.9, I2 57.0%, low CoE). Furthermore, there was no significant difference in adverse events (AE) between the anti-PD-1/PDL1 agents and second-line chemotherapy (risk ratio 0.68; 95% CI 0.3-1.4; I2 97.0%, low CoE).Conclusion: The present meta-analysis and systematic review provide strong evidence that anti-PD-1/PD-L1 agents could improve overall survival and have similar results in AEs compared with second-line chemotherapy. Further studies will confirm the power of immunotherapy for the treatment of metastatic or locally advanced urothelial bladder carcinoma.

scholarly journals Expression of HER2/neu and Ki-67 in Urothelial Carcinoma and their Relation to Clinicopathological Data: An Egyptian Study

2021 ◽  
Author(s):  
Badawia B Ibrahim ◽  
Samira A Mahmoud ◽  
Alzahraa A Mohamed ◽  
Hala M El Hanbuli
Keyword(s):  
Urothelial Carcinoma ◽  
Bladder Carcinoma ◽  
Histological Grade ◽  
P Value ◽  
Urinary Bladder Carcinoma ◽  
Ki 67 ◽  
Urothelial Bladder Carcinoma ◽  
Cellular Marker ◽  
Urothelial Bladder ◽  
Common Malignancy

Introduction: Bladder cancer is the most common malignancy involving the urinary system and the ninth most common malignancy worldwide. Ki-67 is a nonhistone cellular marker for proliferation. HER2/neu is an oncogene that plays an important role in the pathogenesis of many cancer types. In bladder carcinoma, its clinical significance remains under-investigated and poorly linked to the patients’ clinicopathological features especially with no reported Egyptian study. Aim: The aim of this work was to study the expression of HER2/neu and Ki-67 in urinary bladder carcinoma to evaluate their role in tumourigenesis and their correlation with other available clinicopathological variables associated with urothelial carcinoma. Materials and Methods: This cross-sectional study was conducted at the Department of Pathology, Faculty of Medicine, Cairo University, Egypt. Samples were paraffin blocks from 60 cases diagnosed with urothelial carcinoma underwent radical cystectomy. Ki-67 and HER2/neu immunohistochemical staining was done and of Ki-67 and HER2/neu Immunostaining was recorded. The associations between Ki-67, HER2/neu expressions and clinical and histopathological parameters of urothelial bladder carcinoma was evaluated. Results: The Ki-67 expression had significant association with tumour histological grade and lymphovascular invasion (p-value <0.05). The association of HER2/neu expression had significant association with perineural invasion (p-value <0.05). Conclusion: HER2/neu immunostaining was not associated with most of the clinicopathologic prognostic factors in urothelial bladder carcinoma.

BCL-2, TP53 and BAX protein expression in superficial urothelial bladder carcinoma

2007 ◽  
Vol 250 (2) ◽  
pp. 292-299 ◽  
Author(s):  
Ricardo Gonzalez-Campora ◽  
Guillermo Davalos-Casanova ◽  
Antonio Beato-Moreno ◽  
Antonio Garcia-Escudero ◽  
Maria Jesus Pareja Megia ◽  
...  
Keyword(s):  
Protein Expression ◽  
Bladder Carcinoma ◽  
Urothelial Bladder Carcinoma ◽  
Bax Protein ◽  
Urothelial Bladder

Evaluation of β-catenin expression in muscle-invasive urothelial bladder carcinoma

2014 ◽  
Vol 27 (3) ◽  
pp. 507 ◽  
Author(s):  
MohamedSayed El Gharabawy ◽  
FatmaAhmed Elserafy ◽  
EidAbdel-Rasoul Elsherif ◽  
NohaMohamed Nor-Eldin-Elkady ◽  
TarekMohamed Abdel Elbaky ◽  
...  
Keyword(s):  
Bladder Carcinoma ◽  
Urothelial Bladder Carcinoma ◽  
Urothelial Bladder ◽  
Muscle Invasive
Sign in / Sign up

Export Citation Format

Share Document